Appendix 1.
AACR Task Force on the Treatment and Prevention of Intraepithelial Neoplasia Subcommittees a
Co-Chairs
Joyce O’Shaughnessy, M.D., Baylor-Sammons Cancer Center, US Oncology, Dallas, TX
Gary J. Kelloff, M.D., DCTD, National Cancer Institute, Bethesda, MD
Gary B. Gordon, M.D., Ovation Pharmaceuticals, Lincolnshire, IL
Richard Pazdur, M.D., Division of Oncology Drug Products,
U.S. Food and Drug Administration, Rockville, MD
Background and Conceptual Foundations
Gary J. Kelloff, M.D., Chairperson
 Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
Caroline C. Sigman, Ph.D., Vice Chairperson
 CCS Associates, Mountain View, CA
David L. De Mets, Ph.D.
 University of Wisconsin, Madison, WI
Margaret Foti, Ph.D.
 AACR, Philadelphia, PA
Peter Greenwald, M.D., Dr.P.H.
 Division of Cancer Prevention, National Cancer Institute, Bethesda, MD
Florence Houn, M.D.
 Office of Drug Evaluation III, U.S. Food and Drug Administration, Rockville, MD
Robert J. Temple, M.D.
 Office of Drug Evaluation, U.S. Food and Drug Administration, Rockville, MD
Anthony M. Tremblay
 AACR, Philadelphia, PA
Daniel D. Von Hoff, M.D.
 Arizona Cancer Center, University of Arizona, Tucson, AZ
Prostate and Bladder Cancers
Peter T. Scardino, M.D., Chairperson
 Memorial Sloan-Kettering Cancer Center, New York, NY
William G. Nelson, M.D., Ph.D., Vice Chairperson
 Johns Hopkins Oncology Center, Baltimore, MD
Ivan D. Horak, M.D.
 Pharmacia, Peapack, NJ
Ronald Lieberman, M.D.
 Division of Cancer Prevention, National Cancer Institute, Bethesda, MD
Scott M. Lippman, M.D.
 The University of Texas M. D. Anderson Cancer Center, Houston, TX
Wael A. Sakr, M.D.
 Wayne State University, Harper Hospital, Detroit, MI
Dan Shames, M.D.
 Urologic Drugs, U.S. Food and Drug Administration, Rockville, MD
Colorectal Cancer
Gary B. Gordon, M.D., Ph.D., Chairperson
 Ovation Pharmaceuticals, Lincolnshire, IL
Monica M. Bertagnolli, M.D., Vice Chairperson
 Brigham and Women’s Hospital, Boston, MA
Carolyn R. Aldige
 Cancer Research Foundation of America, Alexandria, VA
Steven D. Averbuch, M.D.
 AstraZeneca Pharmaceuticals, Wilmington, DE
Mark I. Avigan, M.D.
 Division of Gastrointestinal and Coagulation Drug Products, U.S. Food and Drug Administration, Rockville, MD
Stephen B. Baylin, M.D.
 Johns Hopkins School of Medicine, Baltimore, MD
Charles W. Boone, M.D., Ph.D.
 Massachusetts Institute of Technology, Cambridge, MA
Ernest T. Hawk, M.D., M.P.H.
 Division of Cancer Prevention, National Cancer Institute, Bethesda, MD
Richard Pazdur, M.D.
 Division of Oncology Drug Products, U. S. Food and Drug Administration, Rockville, MD
Lilia Talarico, M.D.
 Division of Gastrointestinal and Coagulation Drug Products, U.S. Food and Drug Administration, Rockville, MD
Breast Cancer
Carol J. Fabian, M.D., Chairperson
 University of Kansas Medical Center, Kansas City, KS
Joyce O’Shaughnessy, M.D., Vice Chairperson
 Baylor-Sammons Cancer Center, US Oncology, Dallas, TX
Matthew S. Mayo, Ph.D.
 University of Kansas Medical Center, Kansas City, KS
Robert Milsted, M.D.
 AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, UK
Michael B. Sporn, M.D.
 Dartmouth Medical School, Hanover, NH
Anna Marie V. Storniolo, M.D.
 Eli Lilly & Company, Indianapolis, IN
Frances M. Visco, J.D.
 National Breast Cancer Coalition, Washington, DC
Grant Williams, M.D.
 Division of Oncology Drug Products, U.S. Food and Drug Administration, Rockville, MD
Aerodigestive Cancers
Andrew J. Dannenberg, M.D., Chairperson
 Weill Medical College of Cornell University, Strang Cancer Prevention Center, New York, NY
Waun Ki Hong, M.D., Vice Chairperson
 The University of Texas M.D. Anderson Cancer Center, Houston, TX
Steven E. Benner, M.D.
 Bristol-Myers Squibb, Wallingford, CT
Adi F. Gazdar, M.D.
 University of Texas Southwestern Medical Center, Hamon Cancer Center, Dallas, TX
Walter Hittelman, Ph.D.
 The University of Texas M.D. Anderson Cancer Center, Houston, TX
David A. Katzka, M.D.
 University of Pennsylvania, Philadelphia, PA
Stephen Lam, M.D.
 British Columbia Cancer Center, Vancouver, BC, Canada
Beverly D. Lyn-Cook, Ph.D.
 National Center for Toxicology Research, Jefferson, AR
Vali Papadimitrakopoulo, M.D.
 The University of Texas M.D. Anderson Cancer Center, Houston, TX
Anil K. Rustgi, M.D.
 University of Pennsylvania, Philadelphia, PA
Lee W. Wattenberg, M.D.
 University of Minnesota, Minneapolis, MN
Gynecological and Skin Cancers
Michele Follen, M.D., Chairperson
 The University of Texas M.D. Anderson Cancer Center, Houston, TX
Frank L. Meyskens, Jr., M.D., F.A.C.P., Vice Chairperson
 Chao Family Comprehensive Cancer Center, University of California, Irvine, CA
David S. Alberts, M.D.
 Arizona Cancer Center, Tucson, AZ
Vicki V. Baker, M.D.
 Wayne State University and The Karmanos Cancer Institute, Ann Arbor, MI
Molly A. Brewer, D.V.M., M.D.
 The University of Texas Houston Medical School and M.D. Anderson Cancer Center, Houston, TX
Patricia Keegen, M.D.
 Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Rockville, MD
David G. Mutch, M.D.
 Washington University, St. Louis, MO
Mack T. Ruffin, M.D., M.P.H.
 University of Michigan, Ann Arbor, MI
Steven P. Stratton, Ph.D.
 Arizona Cancer Center, University of Arizona, Tucson, AZ
Jeffrey S. Weber, M.D., Ph.D.
 University of Southern California, Los Angeles, CA
  • a FDA participation in this Task Force does not represent or imply endorsement of the views of this publication by the Agency or the United States government.